文献速递慢性肾脏病水电解质与酸碱

纠正代谢性酸中毒可改善CKD 3-4期患者肌肉量与肾功能:随机对照试验

Correction of metabolic acidosis improves muscle mass and renal function in chronic kidney disease stages 3 and 4: a randomized controlled trial.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

该单中心开放标签随机平行组试验纳入188例CKD 3-4期且静脉碳酸氢盐<22 mEq/L的患者,干预组在标准治疗基础上口服碳酸氢钠使静脉碳酸氢盐维持于24-26 mEq/L,对照组仅标准治疗。6个月时干预组瘦体重、中臂肌围和eGFR均高于对照组,快速eGFR下降比例更低。

要点

  • CKD 3-4期伴代谢性酸中毒者补碱至碳酸氢盐24-26 mEq/L可保留瘦体重和肾功能
  • 干预组6个月eGFR高于对照组,快速eGFR下降比例更低
  • 该策略安全性良好,支持在CKD 3-4期患者中纠正代谢性酸中毒

核心结论

  • 补充碱剂使静脉碳酸氢盐升至24-26 mEq/L与CKD 3-4期患者瘦体重和肾功能保留相关。

研究设计与样本

  • 单中心、开放标签、随机、前瞻性平行组研究,共纳入188例CKD 3-4期且静脉碳酸氢盐<22 mEq/L的患者。

主要发现

  • 干预组瘦体重为36.8 kg(95%CI 36.5-37.1),对照组为36 kg(95%CI 35.7-36.4),P=0.002。
  • 干预组中臂肌围为22.9 cm(95%CI 22.8-23),对照组为22.6 cm(95%CI 22.5-22.7),P=0.001。
  • 干预组eGFR为32.74 mL/1.73 m2(95%CI 31.5-33.9),对照组为28.2 mL/1.73 m2(95%CI 27-29.4),P≤0.001。
  • 快速eGFR下降在对照组为39例(41.5%),干预组为19例(20.2%),P=0.001。

关键数值与推荐

  • 干预组在KDIGO 2012指南标准治疗基础上口服碳酸氢钠,维持静脉碳酸氢盐24-26 mEq/L;对照组仅标准治疗。
  • 纳入标准为CKD 3-4期且静脉碳酸氢盐<22 mEq/L。

临床怎么用

  • 对CKD 3-4期伴代谢性酸中毒(静脉碳酸氢盐<22 mEq/L)患者,可考虑口服碳酸氢钠将碳酸氢盐纠正至24-26 mEq/L以保留肌肉量和肾功能。

局限性

  • 单中心、开放标签设计可能引入偏倚。
  • 随访仅6个月,长期疗效与安全性未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metabolic acidosis (MA) is associated with a loss of muscle mass and faster deterioration of kidney function in patients with chronic kidney disease (CKD). A few single-centre randomized trials have reported favourable outcomes following correction of MA. Additional good quality evidence on the safety and efficacy of alkali supplementation is required in epidemiologically different patient subsets with CKD. METHODS: A single-centre, open-label, randomized, prospective parallel-group study was conducted to assess the effect of correction of MA on body composition and kidney function. A total of 188 patients with CKD stages 3 and 4, with venous bicarbonate levels <22 mEq/L were randomized. The intervention arm received standard care as per Kidney Disease: Improving Global Outcomes (KDIGO) 2012 guidelines along with oral sodium bicarbonate supplementation to maintain venous bicarbonate levels at 24-26 mEq/L, whereas the control group received standard care alone. The mid-arm muscle circumference (MAMC), lean body mass (LBM) and estimated glomerular filtration rate (eGFR) were compared between the groups at the end of 6 months. RESULTS: The intervention arm showed a higher LBM {36.8 kg [95% confidence interval (CI) 36.5-37.1] versus 36 [35.7-36.4]; P = 0.002} and MAMC [22.9 cm (95% CI 22.8-23) versus 22.6 (22.5-22.7); P = 0.001] when compared with the control group. The GFR in the intervention arm was higher [32.74 mL/1.73 m2 (95% CI 31.5-33.9) versus 28.2 (27-29.4); P ≤ 0.001]. A rapid decline in GFR was documented in 39 (41.5%) patients in the control arm and 19 (20.2%) patients in the intervention arm (P = 0.001). CONCLUSIONS: Alkali supplementation to increase venous bicarbonate levels to 24-26 mEq/L is associated with preservation of LBM and kidney function in patients with CKD stages 3 and 4.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Dubey AK, Sahoo J, Vairappan B, et al. Correction of metabolic acidosis improves muscle mass and renal function in chronic kidney disease stages 3 and 4: a randomized controlled trial. Nephrol Dial Transplant. 2020. PMID: 30053298. doi:10.1093/ndt/gfy214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。